AlphaFold predicted structure
RASA2 · Q15283

Mean pLDDT
82.8/ 100
Confident
850 residues
Confidence breakdown
- Very high(≥ 90)48%
- Confident(70–90)37%
- Low(50–70)7%
- Very low(< 50)9%
Open interactive 3D viewer
AlphaFold (Jumper et al., 2021) · CC BY 4.0
RAS p21 protein activator 2
Annotations refreshed 9 hours ago.
Moderate Evidence (Amber)
Fetal anomalies
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedMonogenic short stature
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownPaediatric or syndromic cardiomyopathy
MONOALLELIC, autosomal or pseudoautosomal, imprinted status unknownRASopathies
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedPigmentary skin disorders
MONOALLELIC, autosomal or pseudoautosomal, NOT imprintedNoonan syndrome
obesity disorder
Abnormality of the skeletal system
osteoarthritis, knee
neurodegenerative disease
smoking behavior
rhinitis
Crohn disease
overnutrition
osteoarthritis, hip
Score is the Open Targets composite evidence score (0-1). Higher = stronger gene-disease association.
Ras GTPase-activating protein 2
Inhibitory regulator of the Ras-cyclic AMP pathway. Binds inositol tetrakisphosphate (IP4)
RASA2 · Q15283

Mean pLDDT
82.8/ 100
Confident
850 residues
Confidence breakdown
AlphaFold (Jumper et al., 2021) · CC BY 4.0